Statins in Patients With Chronic Kidney Disease: A Double-Edged Sword?

Journal of the American College of Cardiology

Volumn 52, Issue 20, 2008, Pages 1679-

  Kassimatis, Theodoros I ^a   Konstantinopoulos, Panagiotis A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1;

CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; GLOMERULUS FILTRATION RATE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FUNCTION; LETTER; META ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BINDING; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; RENAL REPLACEMENT THERAPY; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; T LYMPHOCYTE;

DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY FAILURE, CHRONIC;

EID: 55049121209     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.07.058     Document Type: Letter

References (13)

1. Harper C.R., and Jacobson T.A. Managing dyslipidemia in chronic kidney disease. J Am Coll Cardiol 51 (2008) 2375-2384
2. Strippoli G.F., Navaneethan S.D., Johnson D.W., et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ 336 (2008) 645-651
3. Douglas K., O'Malley P.G., and Jackson J.L. Meta-analysis: the effect of statins on albuminuria. Ann Intern Med 145 (2006) 117-124
4. Sandhu S., Wiebe N., Fried L.F., and Tonelli M. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 17 (2006) 2006-2016
5. Tonelli M., Moye L., Sacks F.M., Cole T., and Curhan G.C. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 14 (2003) 1605-1613
6. Fried L.F., Orchard T.J., and Kasiske B.L. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 59 (2001) 260-269
7. Chen C.L., Huang S.S., and Huang J.S. Cholesterol modulates cellular TGF-beta responsiveness by altering TGF-beta binding to TGF-beta receptors. J Cell Physiol 215 (2008) 223-233
8. Bottinger E.P., and Bitzer M. TGF-beta signaling in renal disease. J Am Soc Nephrol 13 (2002) 2600-2610
9. Kassimatis T.I., Giannopoulou I., Koumoundourou D., Theodorakopoulou E., Varakis I., and Nakopoulou L. Immunohistochemical evaluation of phosphorylated SMAD2/SMAD3 and the co-activator P300 in human glomerulonephritis: correlation with renal injury. J Cell Mol Med 10 (2006) 908-921
10. Goldstein M.R., Mascitelli L., and Pezzetta F. The double-edged sword of statin immunomodulation. Int J Cardiol (2008) In press
11. PLANET II: Prospective Evaluation of Proteinuria and Renal Function in Non-Diabetic Patients With Progressive Renal Disease (2008). http://clinicaltrials.gov/ct2/show/NCT00296400?term=planet&rank=1 ClinicalTrials.gov. Accessed September 18, 2008
12. Fassett R.G., Ball M.J., Robertson I.K., Geraghty D.P., and Coombes J.S. The Lipid lowering and Onset of Renal Disease (LORD) trial: a randomized double blind placebo controlled trial assessing the effect of atorvastatin on the progression of kidney disease. BMC Nephrol 9 (2008) 4
13. Baigent C., and Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int Suppl 63 (2003) S207-S210